Harmony Biosciences Holdings (HRMY) Stock Statistics & Valuation Metrics

Harmony Biosciences Holdings has a market cap or net worth of $1.97B. The enterprise value is $1.81B.

Market Cap

$1.97B

Enterprise Value

$1.81B

Harmony Biosciences Holdings has 58,723,198 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

58,723,198

Owned by Insiders

0.09%

Owned by Institutions

67.88%

Harmony Biosciences Holdings’s return on equity (ROE) is 0.18 and return on invested capital (ROIC) is 13.90%.

Return on Equity (ROE)

0.18

Return on Assets (ROA)

0.12

Return on Invested Capital (ROIC)

13.90%

Return on Capital Employed (ROCE)

0.20

Revenue Per Employee

2.96M

Profits Per Employee

541.59K

Employee Count

293

Asset Turnover

0.68

Inventory Turnover

37.02

The current PE Ratio of Harmony Biosciences Holdings is 11.11. Harmony Biosciences Holdings’s PEG ratio is -2.25.

PE Ratio

11.11

PS Ratio

2.03

PB Ratio

1.86

Price to FCF

6.22

Price to Operating Cash Flow

6.19

PEG Ratio

-2.25

In the last 12 months, Harmony Biosciences Holdings had revenue of 868.45M and earned 158.69M in profits. Earnings per share was 2.76.

Revenue

868.45M

Gross Profit

670.11M

Operating Income

208.47M

Pretax Income

215.06M

Net Income

158.69M

EBITDA

255.05M

Earnings Per Share (EPS)

2.76

In the last 12 months, operating cash flow was 323.04M and capital expenditures -107,000, giving a free cash flow of 322.93M billion.

Operating Cash Flow

323.04M

Free Cash Flow

322.93M

Free Cash Flow per Share

5.53

Harmony Biosciences Holdings pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

16.10%

Earnings Yield

8.95%

Beta

1.06

52-Week Price Change

3.76%

50-Day Moving Average

39.42

200-Day Moving Average

34.63

Relative Strength Index (RSI)

38.04

Average Volume (3m)

994.60K

Harmony Biosciences Holdings upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 04, 2026

Next Earnings Date

Mar 02, 2027

Ex-Dividend Date

―

Harmony Biosciences Holdings as a current ratio of 3.60, with Debt / Equity ratio of 27.53%

Current Ratio

3.60

Quick Ratio

3.58

Debt to Market Cap

0.11

Net Debt to EBITDA

-2.01

Interest Coverage Ratio

14.23

In the past 12 months, Harmony Biosciences Holdings has paid 56.38M in taxes.

Income Tax

56.38M

Effective Tax Rate

0.26

Harmony Biosciences Holdings EV to EBITDA ratio is 5.56, with an EV/FCF ratio of 4.67.

EV to Sales

1.52

EV to EBITDA

5.56

EV to Free Cash Flow

4.67

EV to Operating Cash Flow

4.67

Harmony Biosciences Holdings has $771.14M in cash and marketable securities with $149.10M in debt, giving a net cash position of $622.03M billion.

Cash & Marketable Securities

$771.14M

Total Debt

$149.10M

Net Cash

$622.03M

Net Cash Per Share

$10.59

Tangible Book Value Per Share

$17.13

Gross margin is 74.03%, with operating margin of 22.17%, and net profit margin of 18.05%.

Gross Margin

74.03%

Operating Margin

22.17%

Pretax Margin

23.55%

Net Profit Margin

18.05%

EBITDA Margin

27.41%

EBIT Margin

24.85%

The average price target for Harmony Biosciences Holdings is $47.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

$47.50

Price Target Upside

38.81% Upside

Analyst Consensus

Moderate Buy

Analyst Count

8

Revenue Growth Forecast

19.79%

EPS Growth Forecast

-4.89%

Smart Score

7

AI Score

74